Superstar Stocks
Boston Scientific still has around 50% of the stent market share in the U.S. and did its own study, which showed no significant difference between Taxus and Cypher.
Nevertheless, Boston Scientific shares have plunged from a high in the mid-$40s to $24.59 as of Friday's close. Investors now have a great opportunity in Boston Scientific. With a forward P/E of 13 and a P/E-to-growth ratio of just over 1, the stock is cheap. J&J trades at a forward P/E of 16.5 based on 2006 estimates of $3.77 per share; Boston Scientific would be valued at more than $31 if given the same multiple, based on its 2006 consensus estimates of $1.90 per share. As a potential catalyst for that multiple expansion, the company is coming out with a second-generation stent, the Taxus Liberte, that has already added to its market share in Europe. Boston Scientific has a third-generation stent that will come into the market in 2009. This is not a one-trick pony. Boston Scientific has a tremendous amount of cash flow from stent sales that will fund its already large research and development effort. It has several devices coming out, including a leadless defibrillator, vascular closure devices, and disposable endoscopes. Boston Scientific will enter the Japanese market in 2007, and it still has around a 50% market share in the U.S. With a renewed marketing campaign, an aging population that fuels stent industry growth, and new products emerging, Boston Scientific is a buy right here. Potential pitfalls are current patent litigation and an overhaul of the Medicare system as most patients are mature adults. I do not believe either of these will be a problem. The trick is over, it's time for a treat. Charlie Brown may never get to kick that football, but Boston Scientific investors will soon be scoring points again. Happy Halloween.TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn MoreOptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn MoreReal Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn MoreStocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,468.15 | 1,312.98 | 2,837.00 | 15.81 |
Oil *
101.93
|
|
UP
48.29 |
DOWN
0.34 |
DOWN
0.36 |
DOWN
0.44 |
10 Yr
1.58%
SPDR Gold
151.65
|
|
+0.39%
|
-0.03%
|
-0.01%
|
-2.71%
|
Data delayed 20 minutes |


Connect with TheStreet